Sign in Subscribe
Cancer research

Breakthrough in Understanding Bone Metastasis: CRISPR Activation Screen Identifies Key Regulator

Strategic Insights

— 1 min read

Research conducted by the University of Texas MD Anderson Cancer Center has shed light on the complex process of bone metastasis, revealing a key regulator in the development of this devastating cancer. According to study results published in Science Translational Medicine, acyl-coenzyme A (CoA) binding protein (ACBP) has been identified as a driver of bone metastasis.

The research used an in vivo CRISPR activation screening system to pinpoint the role of lipid metabolism in bone metastasis. The study found that overexpression of wild-type ACBP in nonmetastatic and weakly metastatic cancer cells stimulated fatty acid oxidation (FAO) and bone metastasis. Conversely, knockout of ACBP in highly bone metastatic cancer cells abrogated metastatic bone colonization.

Key Takeaways:

  • ACBP has been identified as a key regulator of bone metastasis in cancer cells.
  • Overexpression of wild-type ACBP stimulates fatty acid oxidation and bone metastasis in nonmetastatic and weakly metastatic cancer cells.
  • Knockout of ACBP in highly bone metastatic cancer cells abrogates metastatic bone colonization.
  • Mechanistically, ACBP-mediated FAO increased ATP and NADPH production, reduced reactive oxygen species, and inhibited lipid peroxidation and ferroptosis.
  • ACBP expression correlates with metabolic signaling, bone metastatic ability, and poor clinical outcomes.
  • Agents that target FAO or induce ferroptosis represent a promising therapeutic approach for treating bone metastases.

Statistics:

  • 17% of cancer patients develop bone metastasis (Source: Science Translational Medicine).
  • Bone metastasis is associated with substantial morbidity and mortality (Source: Science Translational Medicine).
  • The research used an in vivo CRISPR activation screening system to identify ACBP as a driver of bone metastasis (Source: Science Translational Medicine).
  • Acyl-coenzyme A (CoA) binding protein (ACBP) was identified as a key regulator of bone metastasis (Source: Science Translational Medicine).
  • Fatty acid oxidation (FAO) increased ATP and NADPH production in cancer cells (Source: Science Translational Medicine).

Sources:

  • Science Translational Medicine, 2025;17(799).
  • Li Ma, et al. (2025). In Vivo Crispr Activation Screen Identifies Acyl-coa-binding Protein As a Driver of Bone Metastasis. Science Translational Medicine.
  • NewsRx. Studies from University of Texas MD Anderson Cancer Center Update Current Data on Cancer (In Vivo Crispr Activation Screen Identifies Acyl-coa-binding Protein As a Driver of Bone Metastasis). Health & Medicine Week. June 20, 2025; p 5068.

Read more